The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.
Botulinum toxin type A (BTX-A) has been shown to be a safe and effective treatment for primary focal hyperhidrosis. However, the effect of BTX-A therapy on quality of life (QOL) in patients with this condition has only recently begun to be studied in controlled clinical trials. ⋯ Hyperhidrosis is associated with a substantial QOL burden; however, QOL is markedly improved with BTX-A treatment.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Imiquimod 5% cream has been investigated for non-surgical treatment of superficial and nodular basal cell carcinoma (BCC) tumours. ⋯ In the superficial study, the complete response rate of 87% in the 3 days per week with occlusion group was similar to that of daily and 5 days per week dosing without occlusion in a previous 12-week study and one study of daily dosing without occlusion for 6 weeks. All treatment groups had acceptable safety profiles in both studies. Occlusion did not have a statistically significant effect on efficacy for either superficial or nodular BCC tumours.